MSD to buy VC-backed Themis

MSD has agreed to acquire Vienna-based Themis, a provider of immunomodulation therapies for infectious diseases and cancer.

26 May 2020•5 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Healthcare M&A Deals Briefs